NCT01048918
Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer No drug interventions Not Available Not Available completed NCT00662025
Study Of Sunitinib With Capecitabine In Breast Cancer treatment 2 completed NCT02338167
Praegnant Breast Cancer: Early/Advanced/Metastatic No drug interventions Not Available Not Available recruiting NCT04901299
Fulvestrant + Neratinib In Breast Cancer treatment 2 withdrawn NCT00140140
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer treatment 1 / 2 terminated NCT03147287
Palbociclib After CDK and Endocrine Therapy (PACE) treatment 2 active_not_recruiting NCT02393287
Retroprospective Real Life Observatory of Eribulin No drug interventions Not Available Not Available completed NCT03876587
Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC treatment 2 unknown_status NCT04669587
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) treatment 1 / 2 unknown_status NCT04315233
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics treatment 1 recruiting NCT04298333
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer supportive_care 1 completed NCT06414733
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors No drug interventions treatment 1 not_yet_recruiting NCT04354233
A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer No drug interventions supportive_care Not Available recruiting NCT01725633
Aerobic Training in Metastatic Breast Cancer No drug interventions supportive_care Not Available completed NCT00645333
Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer treatment 1 / 2 completed NCT04176354
Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy Not Available Not Available completed NCT05732051
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients No drug interventions prevention 2 recruiting NCT02524951
Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer treatment 1 terminated NCT04042051
Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer treatment 1 terminated NCT01596751
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer treatment 1 / 2 completed NCT03045653
Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer treatment 2 completed NCT02322853
A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors treatment 2 terminated NCT02723877
PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) treatment 1 / 2 completed NCT06023277
A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer No drug interventions treatment 1 / 2 not_yet_recruiting NCT01360177
Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers No drug interventions treatment Not Available withdrawn NCT01978977
Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT01730677
Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab treatment 2 unknown_status NCT02528747
A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate No drug interventions Not Available Not Available completed NCT05662345
ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC) No drug interventions Not Available Not Available recruiting NCT03824145
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer No drug interventions supportive_care Not Available recruiting NCT02188745
ER Reactivation Therapy for Breast Cancer treatment 2 completed NCT02632045
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer treatment 2 active_not_recruiting NCT01361945
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer treatment 1 / 2 withdrawn NCT02338245
Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab treatment 2 completed NCT02392845
A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study treatment 1 completed NCT00911898
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers treatment 1 completed NCT06062498
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT00358098
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer No drug interventions Not Available Not Available terminated NCT04120298
Effects of Exercise in Patients With Metastatic Breast Cancer No drug interventions supportive_care Not Available active_not_recruiting NCT01149798
A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer treatment 2 completed NCT04167605
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases No drug interventions Not Available Not Available recruiting NCT04483505
Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. other 1 completed NCT03577197
Southeast Netherlands Advanced Metastatic Breast Cancer Registry No drug interventions Not Available Not Available recruiting NCT03603197
BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer treatment 2 completed NCT03789097
Vaccination With Flt3L, Radiation, and Poly-ICLC treatment 1 / 2 recruiting NCT00480597
Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer treatment 2 completed NCT02137083
A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer treatment 2 completed NCT02924883
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy treatment 2 completed NCT04603183
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL treatment 2 active_not_recruiting NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors treatment 1 recruiting NCT04253561
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients treatment 1 recruiting NCT02909361
Fulvestrant 500mg in Patients With Advanced Breast Cancer Not Available Not Available unknown_status NCT01120561
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer Not Available Not Available no_longer_available NCT00986661
A Study to Assess PV-10 Chemoablation of Cancer of the Liver treatment 1 active_not_recruiting NCT00517361
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer treatment 2 terminated NCT06202261
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer treatment 1 / 2 recruiting NCT05559528
BRaziLian outcomE for metAStatic breasT Cancer No drug interventions Not Available Not Available recruiting NCT03505528
An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer treatment 1 completed NCT01240928
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer treatment 1 withdrawn NCT01733628
Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer No drug interventions Not Available Not Available completed NCT02447328
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer other 4 completed NCT06405828
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer No drug interventions supportive_care Not Available recruiting NCT06106711
The Impact of Adverse Events, Produced by Antibodies Conjugates, on Quality of Life in Patients With Metastatic Breast Cancer: Multicentric, Observational Study (EVA). No drug interventions Not Available Not Available not_yet_recruiting NCT03079011
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection treatment 3 active_not_recruiting NCT00679211
A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer treatment 2 completed NCT05065411
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer treatment 3 terminated NCT06439693
The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT04165993
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer treatment 2 active_not_recruiting NCT01322893
Enumeration and Molecular Characterization of Circulating Tumour Cells in Women With Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT06110793
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer treatment 1 / 2 recruiting NCT01985893
Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer treatment 2 withdrawn NCT02594371
Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer treatment 3 completed NCT02632071
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer treatment 1 completed NCT00240071
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca. treatment 2 completed NCT05574478
Metastatic Breast Cancer-Specific Prognostic Tool No drug interventions Not Available Not Available active_not_recruiting NCT00614978
Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer treatment 1 completed NCT05302778
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer No drug interventions Not Available Not Available recruiting NCT01009788
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer treatment 2 active_not_recruiting NCT04407988
Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer treatment 2 unknown_status NCT03507088
Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer No drug interventions treatment Not Available completed NCT00387907
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer treatment 2 completed NCT02028507
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors treatment 3 completed NCT04030507
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer No drug interventions screening Not Available recruiting NCT00270907
CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer treatment 1 completed NCT00148707
Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer treatment 2 completed NCT05207709
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype treatment 3 recruiting NCT01990209
Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) treatment 2 completed NCT02238509
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies treatment 2 unknown_status NCT01185509
Trastuzumab and Vinorelbine in Advanced Breast Cancer treatment 2 terminated NCT05596409
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study treatment 2 recruiting NCT01482156
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors treatment 1 completed NCT04992156
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET Not Available Not Available completed NCT03568656
Study to Evaluate CCS1477 in Advanced Tumours treatment 1 / 2 recruiting NCT00225056
Phase II Study of Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Patients With Metastatic Breast Carcinoma treatment 2 terminated NCT05206656
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer treatment 2 completed NCT00624156
Expressive Writing and Adjustment to Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT00903656
Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy treatment 2 terminated NCT00274456
Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer treatment 2 completed NCT02129556
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer treatment 1 / 2 completed NCT06369285
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT01654185
Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer treatment 2 completed NCT01044485
Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer treatment 1 / 2 completed NCT03086785
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer treatment 2 unknown_status NCT03166085
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer treatment 1 completed NCT04609215
ImmunoBreast - A Phase Ib Study No drug interventions treatment 1 / 2 unknown_status NCT03322215
HR+/HER2- Advanced Breast Cancer and Endocrine Resistance treatment 2 terminated NCT02186015
Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D) treatment 2 completed NCT02607215
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC treatment 2 unknown_status NCT05266937
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel treatment 2 active_not_recruiting NCT06342037
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial treatment 2 recruiting NCT05285332
Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy No drug interventions treatment Not Available not_yet_recruiting NCT03002532
Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer No drug interventions treatment Not Available unknown_status NCT00454532
A Phase I/II Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer treatment 1 / 2 completed NCT00715832
A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer No drug interventions treatment 1 unknown_status NCT00924352
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer treatment 1 / 2 completed NCT04382352
B002 in Patients With HER2-positive Breast Cancer No drug interventions treatment 1 completed NCT02223052
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies treatment 1 completed NCT00855452
Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors No drug interventions treatment 2 completed NCT00694252
Lapatinib and Circulating Tumor Cells in Breast Cancer treatment 2 completed NCT00370552
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer treatment 2 completed NCT02655952
Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients treatment 1 completed NCT01075100
Ixabepilone + Carboplatin Metastatic Breast Cancer treatment 2 completed NCT02126800
Rapid Medical Donation Programme for Breast Cancer No drug interventions Not Available Not Available unknown_status NCT00354900
Phase I Study of Aprotinin in Advanced Breast Cancer treatment 1 terminated NCT00169000
Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers treatment 1 completed NCT01862900
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions treatment 1 completed NCT04163159
Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica No drug interventions Not Available Not Available unknown_status NCT01589159
A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes treatment 2 completed NCT01231659
Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer treatment 2 completed NCT01401959
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy treatment 2 completed NCT00907959
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer treatment 2 unknown_status NCT02645175
Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue No drug interventions treatment 2 terminated NCT01111175
Triple Negative Breast Cancer Biomarker Study No drug interventions Not Available Not Available completed NCT06525675
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) Not Available Not Available active_not_recruiting NCT04020575
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) No drug interventions treatment 1 recruiting NCT02257775
Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer No drug interventions Not Available Not Available terminated NCT01802970
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients treatment 1 completed NCT00943670
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression treatment 2 completed NCT01910870
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes treatment 2 terminated NCT05143970
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors treatment 1 recruiting NCT03950570
ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer treatment 1 / 2 active_not_recruiting NCT00148070
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer treatment 2 completed NCT05810870
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin treatment 2 recruiting NCT01007942
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer treatment 3 completed NCT04368442
Cohort Study of Patients With HER2-negative MBC and BRCA 1/2 Pathogenic Mutation No drug interventions Not Available Not Available unknown_status NCT02536742
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer treatment 2 completed NCT04150042
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells treatment 1 recruiting NCT05954442
Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype treatment 3 recruiting NCT00759642
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy treatment 2 terminated NCT01847599
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib No drug interventions treatment Not Available terminated NCT00236899
Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC treatment 3 completed NCT06145399
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer No drug interventions diagnostic 0 withdrawn NCT01818999
Ixabepilone and SBRT For Metastatic Breast Cancer treatment 2 withdrawn NCT01512199
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) treatment 1 / 2 terminated NCT04924699
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer treatment 2 / 3 recruiting NCT05029999
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer treatment 1 recruiting NCT04115306
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer treatment 1 / 2 recruiting NCT05508906
Phase 1b Combo w/ Ribociclib and Alpelisib treatment 1 recruiting NCT03132506
E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research No drug interventions Not Available Not Available unknown_status NCT01315106
High Resolution 3D Diffusion-weighted Breast MRI No drug interventions Not Available Not Available active_not_recruiting NCT04240106
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) treatment 2 completed NCT05043506
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies Not Available Not Available completed NCT04332549
To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer No drug interventions treatment 1 withdrawn NCT01919749
A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer No drug interventions treatment Not Available completed NCT01835236
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC treatment 2 completed NCT02682836
Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study No drug interventions supportive_care Not Available completed NCT00988936
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug No drug interventions Not Available 2 completed NCT00574236
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer treatment 2 terminated NCT01036113
A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer treatment 2 terminated NCT01266213
Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women treatment 2 unknown_status NCT03492918
Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16) treatment 2 unknown_status NCT03998618
Telephone Support for Metastatic Breast Cancer Patients No drug interventions supportive_care Not Available completed NCT02018419
Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients No drug interventions treatment 1 / 2 withdrawn NCT05833919
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients treatment 2 active_not_recruiting NCT05455619
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer treatment 1 / 2 recruiting NCT00555919
ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer treatment 2 completed NCT01240941
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer treatment 2 withdrawn NCT02980341
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer No drug interventions treatment 1 / 2 completed NCT00632541
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer treatment 2 terminated NCT04360941
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer other 1 recruiting NCT05427617
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer Not Available Not Available completed NCT04602117
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer treatment 1 withdrawn NCT01421017
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases treatment 1 / 2 completed NCT00534417
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer treatment 2 completed NCT03913234
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients treatment 1 / 2 unknown_status NCT00825734
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer treatment 1 / 2 completed NCT00868634
Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer treatment 3 completed NCT03161834
Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer No drug interventions Not Available Not Available withdrawn NCT03272334
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer treatment 1 / 2 recruiting NCT01548534
A Randomised Study of Docosahexaenoic Acid (DHA) in Metastatic Breast Cancer No drug interventions supportive_care 3 terminated NCT04170634
Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study No drug interventions Not Available Not Available recruiting NCT01377324
Molecular Imaging of Fulvestrant Effects on Availability of ER Binding Sites No drug interventions diagnostic 2 completed NCT02073916
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer treatment 1 completed NCT05716516
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER) treatment 2 recruiting NCT03238196
Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer treatment 1 active_not_recruiting NCT06428396
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) treatment 2 not_yet_recruiting NCT00570258
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy treatment 2 terminated NCT00225758
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy treatment 2 terminated NCT05025735
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer treatment 2 unknown_status NCT04660435
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer No drug interventions Not Available Not Available recruiting NCT00380835
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer treatment 2 withdrawn NCT01084863
Evaluate Safety, Efficacy and Pharmacokinetics treatment 1 / 2 completed NCT04061863
Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer treatment 1 / 2 unknown_status NCT01912963
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer treatment 2 terminated NCT02649686
Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab other 1 completed NCT03473639
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy treatment 1 completed NCT00661739
A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer treatment 1 completed NCT02536339
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy treatment 2 completed NCT03997539
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer treatment 2 unknown_status NCT02511639
Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients treatment 3 completed NCT02329639
Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy No drug interventions Not Available Not Available unknown_status NCT02312622
Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer treatment 2 completed NCT04541225
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors No drug interventions treatment 1 terminated NCT00065325
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer treatment 3 completed NCT02792725
Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer Not Available Not Available approved_for_marketing NCT00197925
Dendritic Cell Based Therapy of Metastatic Breast Cancer No drug interventions treatment 1 / 2 terminated NCT00403130
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer treatment 2 completed NCT06507930
The COMPASSION Study No drug interventions health_services_research Not Available not_yet_recruiting NCT02479230
Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients treatment 1 completed NCT02362230
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy treatment 2 terminated NCT01881230
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) treatment 2 / 3 completed NCT02383030
Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients diagnostic 3 unknown_status NCT04188548
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer treatment 1 active_not_recruiting NCT01550848
A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer treatment 2 completed NCT02505048
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature treatment 2 completed NCT06557148
A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer No drug interventions Not Available Not Available recruiting NCT06074757
Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study treatment 1 completed NCT03355157
A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). treatment 4 unknown_status NCT01056757
Treatment With Ribavirin for Patients With Metastatic Breast Cancer treatment 1 / 2 terminated NCT00522457
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy treatment 2 terminated NCT06324357
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread treatment 1 / 2 recruiting NCT05753657
A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer. treatment 0 recruiting NCT05765357
Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers treatment 1 completed NCT06533826
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd treatment 2 not_yet_recruiting NCT03328026
Combination Study of SV-BR-1-GM With Retifanlimab treatment 1 / 2 enrolling_by_invitation NCT01543126
IL-6 and IL-8 Level of Blood and Pleural Effusion During Chemotherapy in Metastatic Breast Cancer No drug interventions Not Available Not Available terminated NCT00618826
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer treatment 2 completed NCT05868226
PRE-I-SPY Phase I/Ib Oncology Platform Program treatment 1 recruiting NCT05696626
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation treatment 3 recruiting NCT04140526
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC treatment 1 / 2 recruiting NCT05155566
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings. No drug interventions Not Available Not Available completed NCT00584766
Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer No drug interventions treatment 2 completed NCT05693766
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort treatment 2 recruiting NCT04965766
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer No drug interventions treatment 2 recruiting NCT06525766
Adaptive Therapy With Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer treatment 2 not_yet_recruiting NCT00847366
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma treatment Not Available completed NCT02738866
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor treatment 2 active_not_recruiting NCT04411966
Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer No drug interventions diagnostic Not Available completed NCT06321666
Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone No drug interventions diagnostic Not Available active_not_recruiting NCT01576666
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors other 1 completed NCT04941365
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy No drug interventions diagnostic Not Available withdrawn NCT03638765
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer No drug interventions treatment 1 unknown_status NCT00976365
Evaluation of the Safety and Efficacy of THL-P in Metastatic Breast Cancer No drug interventions treatment 2 completed NCT03344965
Olaparib In Metastatic Breast Cancer treatment 2 active_not_recruiting NCT03608865
Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing treatment 2 completed NCT03807765
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases treatment 1 active_not_recruiting NCT01640665
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors treatment 1 completed NCT00250874
Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer treatment 2 unknown_status NCT05054374
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer treatment 1 / 2 completed NCT01127074
Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422) No drug interventions treatment 1 completed NCT01797120
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI treatment 2 completed NCT01784120
A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer treatment 2 unknown_status NCT02473120
Study of ESR1 Mutations in Metastatic Breast Cancer No drug interventions other Not Available completed NCT04703920
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer treatment 1 recruiting NCT00212082
Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer treatment 2 completed NCT03709082
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer treatment 1 / 2 terminated NCT02000882
STAR Cape+BKM120 MBC With Brain Met treatment 2 completed NCT00394082
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer treatment 2 completed NCT03243331
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer treatment 1 completed NCT05227131
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer treatment 2 withdrawn NCT03685331
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer treatment 1 active_not_recruiting NCT00788931
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer treatment 1 completed NCT04573231
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer diagnostic 2 recruiting NCT01338831
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer No drug interventions treatment 1 completed NCT03073473
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers No drug interventions Not Available Not Available terminated NCT03456973
Nurse AMIE: A Tablet Based Supportive Care Platform in Metastatic Breast Cancer No drug interventions supportive_care Not Available completed NCT04389073
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine treatment 2 unknown_status NCT00932373
A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen treatment 1 completed NCT01611727
Open-Label,Non-Randomized Trial of Cisplatin Chemotherapy in BRCA1-Positive Metastatic Breast Cancer Patients treatment 2 completed NCT01237327
Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer treatment 3 completed NCT00204776
XELOX for Metastatic Breast Cancer Not Available 2 completed NCT03758976
Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec) No drug interventions Not Available Not Available recruiting NCT04293276
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer treatment 2 active_not_recruiting NCT03591276
Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer No drug interventions treatment 1 / 2 unknown_status NCT04937660
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC No drug interventions Not Available Not Available recruiting NCT01477060
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer treatment 2 terminated NCT06180460
CALM: Managing Distress in Malignant Brain Cancer No drug interventions supportive_care Not Available recruiting NCT01773460
Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane treatment 3 terminated NCT03362060
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer treatment 1 active_not_recruiting NCT05720260
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC treatment 2 recruiting NCT02008994
Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer No drug interventions treatment 2 terminated NCT00159094
A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer treatment 2 unknown_status NCT03786094
Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer treatment 3 terminated NCT02783794
BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer treatment 2 completed NCT02020291
Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer treatment 1 completed NCT02719691
Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer treatment 1 completed NCT03732391
Phase 2 Study of Pembrolizumab+Carboplatin in Breast Related Cancer Antigens-related Metastatic Breast Cancer (PEMBRACA) treatment 2 completed NCT01439191
Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer treatment 2 completed NCT00165880
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine diagnostic 2 terminated NCT00134680
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC treatment 2 completed NCT01928680
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer treatment 2 unknown_status NCT05735080
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer No drug interventions treatment 1 / 2 recruiting NCT04597580
Personalised Disease Monitoring in Metastatic Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT05303129
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor. No drug interventions other Not Available active_not_recruiting NCT05629429
Olaparib Maintenance Therapy in Metastatic Breast Cancer treatment 2 recruiting NCT02041429
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca treatment 1 / 2 completed NCT04770129
Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey No drug interventions Not Available Not Available completed NCT05440929
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians No drug interventions Not Available Not Available recruiting NCT01660529
Multi-peptide Vaccine With Basilixumab for Breast Cancer No drug interventions treatment 0 completed NCT02064829
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer treatment Not Available completed NCT02657889
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer treatment 1 / 2 completed NCT03644589
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer treatment 2 withdrawn NCT01283789
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer treatment 2 unknown_status NCT04034589
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer treatment 2 unknown_status NCT02418689
Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens treatment 2 completed NCT05846789
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers treatment 2 recruiting NCT04556292
A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients No drug interventions treatment 2 unknown_status NCT06320392
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT03890744
ModraDoc006/r in Patients With Breast Cancer treatment 2 completed NCT01555944
Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines No drug interventions Not Available Not Available completed NCT05940844
Study of OB-002 in Patients With Refractory Metastatic Cancer No drug interventions treatment 1 not_yet_recruiting NCT06338644
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients. Not Available Not Available not_yet_recruiting NCT05012644
Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone Not Available Not Available completed NCT03266744
Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study No drug interventions other Not Available unknown_status NCT04609540
Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC Not Available Not Available unknown_status NCT00717340
A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer treatment 1 completed NCT00615940
Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer treatment 2 completed NCT00262067
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) treatment 3 unknown_status NCT00192101
Gemcitabine Plus Cisplatin Single Dose Versus Split Dose in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer After Failure of Anthracyclines and/or Taxanes treatment 2 completed NCT02649101
Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer treatment 2 unknown_status NCT03442504
Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer No drug interventions other Not Available active_not_recruiting NCT04123704
Sitravatinib in Metastatic Breast Cancer treatment 2 terminated NCT01045304
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer treatment 2 completed NCT04262804
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC treatment 2 active_not_recruiting NCT01053104
Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring No drug interventions Not Available Not Available completed NCT00608972
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer treatment 2 completed NCT00251472
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer treatment 2 completed NCT01004172
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases treatment 2 completed NCT00764972
Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer treatment 1 / 2 unknown_status NCT00696072
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic treatment 2 completed NCT06076772
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients Not Available Not Available not_yet_recruiting NCT05002868
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors No drug interventions treatment 1 completed NCT06246968
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer treatment 1 recruiting NCT02662868
Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments No drug interventions Not Available Not Available completed NCT03637868
Eribulin in Brain Metastases From HER2-negative Breast Cancer treatment 2 withdrawn NCT01262469
Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer. treatment 2 completed NCT04251169
Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression treatment 2 terminated NCT00706069
Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer treatment 1 completed NCT01116869
China CellSearch Study No drug interventions Not Available Not Available completed NCT00191269
Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen treatment 2 completed NCT00212069
Serum Proteomics to Predict Gemcitabine Sensitivity in Breast Cancer treatment 2 completed NCT00509769
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer treatment 2 completed NCT01176669
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients treatment 2 completed NCT01501669
Irinotecan/Capecitabine Versus Capecitabine in Patients Treated With A/T for HER2 Negative Metastatic Breast Cancer treatment 3 unknown_status NCT06099769
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer treatment 2 recruiting NCT00274469
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer treatment 2 completed NCT05033769
Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer treatment 4 unknown_status NCT00456846
First Line Therapy for Patients With Metastatic Breast Cancer treatment 2 terminated NCT02202746
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer treatment 2 terminated NCT04129346
Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB No drug interventions supportive_care Not Available completed NCT02592746
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC treatment 2 unknown_status NCT03323346
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer treatment 2 recruiting NCT02809846
Quell Opioid Reduction and Pain Relief in Patients With Cancer No drug interventions supportive_care Not Available terminated NCT00725946
Pilot Study to Determine Radioiodide Accumulation and Dosimetry in Breast Cancers Using 124I PET/CT diagnostic 0 terminated NCT02175446
Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients treatment 2 unknown_status NCT05759546
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer treatment 2 recruiting NCT02144012
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer treatment 3 terminated NCT03910712
Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC treatment 2 unknown_status NCT06532812
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer treatment 1 / 2 recruiting NCT02072512
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer treatment 2 unknown_status NCT05769010
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases treatment 2 recruiting NCT05301010
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients treatment 3 completed NCT04088110
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer treatment 2 unknown_status NCT01278810
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients treatment 1 unknown_status NCT05217381
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status No drug interventions Not Available Not Available completed NCT03321981
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. treatment 2 completed NCT06343181
A Qualitative Study on Treatment Adherence in Patients With Metastatic Breast Cancer No drug interventions Not Available Not Available recruiting NCT05907681
Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M) No drug interventions Not Available Not Available recruiting NCT00905281
Study of Impact of Routine "Clinical Cancer Department/Supportive Care Department" Consultation on the Prescription of an Additional Line of Chemotherapy No drug interventions supportive_care Not Available completed NCT02284581
Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments No drug interventions Not Available Not Available recruiting NCT04963595
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer treatment 2 unknown_status NCT04889495
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer Not Available Not Available not_yet_recruiting NCT00212095
Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer treatment 2 completed NCT01423695
Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer treatment 2 completed NCT00364195
Tesmilifene in Combination With Docetaxel in the Treatment of Metastatic Breast Cancer treatment 2 completed NCT01837095
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer No drug interventions treatment 1 completed NCT02263495
Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer treatment 2 completed NCT05161195
Roll-over Study to Allow Continued Access to Ribociclib treatment 4 recruiting NCT06135714
Metastasis-directed Therapy for Oligometastases of Breast Cancer No drug interventions treatment 3 recruiting NCT03988114
A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer treatment 4 withdrawn NCT01074814
Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca No drug interventions basic_science 0 completed NCT01433614
Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer treatment 3 completed NCT00369655
VEGF Trap in Treating Patients With Metastatic Breast Cancer treatment 2 completed NCT01701050
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index No drug interventions Not Available Not Available completed NCT03427450
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System No drug interventions Not Available Not Available completed NCT00367250
Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer treatment 1 unknown_status NCT03878823
Safety and Pharmacokinetics of ODM-209 No drug interventions treatment 1 / 2 completed NCT01380808
Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC) treatment 2 completed NCT01027208
A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline treatment 2 completed NCT04872608
A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer treatment 1 withdrawn NCT04983238
Evaluation of Safety and Efficacy of Sodium Thiosulfate (BYON5667) Eye Drops to Reduce Ocular Toxicity in Cancer Patients Treated With SYD985 prevention 1 / 2 completed NCT00912938
Evaluate the Relationship of Bone Remodeling Markers for Skeletal Complications in Metastatic Breast Cancer Patients diagnostic 4 unknown_status NCT06016738
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer treatment 3 recruiting NCT01656538
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer treatment 2 completed NCT04869943
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer treatment 3 terminated NCT06263543
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC treatment 2 recruiting NCT02544243
Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer treatment 2 unknown_status NCT05636943
Couples' QOL in Metastatic Breast Cancer No drug interventions supportive_care Not Available recruiting NCT03057743
Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer No drug interventions Not Available Not Available terminated NCT05954143
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer treatment 2 active_not_recruiting NCT03787303
Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma treatment 2 terminated NCT01855503
Breast Cancer Molecular Analysis Protocol No drug interventions Not Available Not Available completed NCT04659603
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors treatment 2 active_not_recruiting NCT05708703
Assessing the Time Demands of Cancer No drug interventions Not Available Not Available recruiting NCT02664103
Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer treatment 2 completed NCT03280303
Palbociclib in Real World Practice No drug interventions Not Available Not Available completed NCT02423603
PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer treatment 2 active_not_recruiting NCT03854903
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor treatment 1 active_not_recruiting NCT00337103
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes treatment 3 completed NCT00051103
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. No drug interventions treatment 2 completed NCT02687490
Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer treatment 2 completed NCT03642990
NR in Chemo-induced Peripheral Neuropathy treatment 2 terminated NCT02444390
Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor No drug interventions screening Not Available completed NCT04367090
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer treatment 1 completed NCT00567190
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer treatment 3 completed NCT01750164
Patient Derived Breast Cancer Xenografts No drug interventions Not Available Not Available terminated NCT03993964
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer treatment 2 unknown_status NCT00477464
Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer treatment 2 completed NCT01132664
Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer treatment 1 / 2 terminated NCT05826964
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer treatment 2 recruiting NCT02210364
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC). treatment 1 completed NCT00214864
A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer treatment 2 completed NCT02310464
Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects treatment 1 completed NCT04350021
Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer Not Available Not Available completed NCT04001621
Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer treatment 2 active_not_recruiting NCT04990921
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer treatment 2 recruiting NCT00216021
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer treatment 2 completed NCT00905021
Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer treatment 1 / 2 terminated NCT01207102
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer treatment 2 terminated NCT01517802
A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate treatment 3 completed NCT02423902
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer treatment 1 / 2 completed NCT01935102
Polymorphism Interaction to Predict Bevacizumab Efficacy No drug interventions Not Available Not Available completed NCT04246502
Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT04212702
ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments Not Available Not Available unknown_status NCT06105684
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer treatment 2 not_yet_recruiting NCT03328884
Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients treatment 2 active_not_recruiting NCT02658084
Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer treatment 1 / 2 terminated NCT04059484
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer treatment 2 active_not_recruiting NCT06298084
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd treatment 1 / 2 recruiting NCT00875979
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab treatment 1 / 2 completed NCT05927779
Study of TFX06 in Women With Advanced Breast Cancer. No drug interventions treatment 1 / 2 recruiting NCT06343987
The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity No drug interventions treatment Not Available recruiting NCT06328387
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer treatment 1 / 2 recruiting NCT00248287
PhII ICb With/Without Erbitux in MBC Pts treatment 2 active_not_recruiting NCT05837533
Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients No drug interventions other Not Available recruiting NCT05955833
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study No drug interventions diagnostic 1 recruiting NCT01414933
High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents No drug interventions Not Available Not Available completed NCT01658033
Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients treatment 2 completed NCT00623233
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer treatment 2 completed NCT04432454
Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation treatment 2 active_not_recruiting NCT01876251
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer treatment 1 terminated NCT01832051
Clinical Value of 89Zr-trastuzumab PET diagnostic 2 completed NCT02313051
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients treatment 2 unknown_status NCT02041351
Biweekly Docetaxel in Patients With Metastatic Breast Cancer. treatment 2 completed NCT03139851
Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide treatment 2 completed NCT02404051
Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer treatment 3 unknown_status NCT06143553
Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC). treatment 3 recruiting NCT04103853
Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer treatment 1 completed NCT03908853
Pain Phenotyping of Patients With Bone Cancer Pain No drug interventions Not Available Not Available unknown_status NCT03555877
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer treatment 2 completed NCT04352777
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer treatment 2 active_not_recruiting NCT00645177
Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer treatment 2 completed NCT01019577
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant treatment 2 completed NCT01495247
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer treatment 1 / 2 terminated NCT03151447
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer No drug interventions treatment 1 unknown_status NCT01939847
IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins No drug interventions treatment Not Available completed NCT00171847
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer treatment 4 terminated NCT01471847
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab treatment 1 completed NCT00333047
Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy treatment 2 / 3 completed NCT01528345
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer treatment 2 terminated NCT03742245
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer treatment 1 recruiting NCT04263298
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer treatment 3 recruiting NCT03409198
Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer treatment 2 completed NCT02802098
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer basic_science 0 completed NCT00842998
Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer treatment 2 unknown_status NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer treatment 1 / 2 recruiting NCT02917005
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer treatment 2 unknown_status NCT01259505
Safety Study of Multiple-Vaccine to Treat Metastatic Breast Cancer No drug interventions treatment 1 completed NCT00597597
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer treatment 2 terminated NCT03669497
Hypo-Fractionated Radiotherapy in Breast Cancer No drug interventions treatment Not Available completed NCT04173897
Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention. No drug interventions other Not Available completed NCT01975597
Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer No drug interventions Not Available Not Available terminated NCT01351597
A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer treatment 2 unknown_status NCT01134497
Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer treatment 2 withdrawn NCT05963997
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer treatment 1 / 2 active_not_recruiting NCT00281697
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) treatment 3 completed NCT02544997
A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway treatment 2 completed NCT03698383
Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer treatment 2 unknown_status NCT05660083
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) treatment 2 recruiting NCT05760183
Discovering Factors in Metastatic Breast Cancer Patients' Clinical Trial Experiences No drug interventions Not Available Not Available not_yet_recruiting NCT02491983
Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer treatment 2 completed NCT05346861
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab treatment 3 recruiting NCT03411161
S 81694 Plus Paclitaxel in Metastatic Breast Cancer treatment 1 / 2 completed NCT02207361
Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer treatment 4 unknown_status NCT00418028
Standard Versus Continuous Capecitabine in Advanced Breast Cancer treatment 2 / 3 completed NCT04030728
Implementing Patients´ Competence in Oral Breast Cancer Therapy No drug interventions Not Available Not Available unknown_status NCT03227328
CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO No drug interventions treatment 2 unknown_status NCT03275311
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008 No drug interventions Not Available Not Available recruiting NCT01320111
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment treatment 2 completed NCT06214793
Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) treatment 2 suspended NCT02538471
LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer No drug interventions treatment 2 terminated NCT04175171
Clinical Trial of Comparative Study of GB221 Pharmacokinetics treatment 1 completed NCT00531271
ABI-008 Trial in Patients With Metastatic Breast Cancer treatment 1 / 2 terminated NCT00958971
Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer treatment 2 completed NCT05804578
Using a Blood Test to Monitor Metastatic Breast Cancer Treatment No drug interventions Not Available Not Available recruiting NCT04834778
A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) No drug interventions treatment 1 completed NCT00627978
Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons treatment 2 completed NCT03251378
A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer treatment 1 active_not_recruiting NCT01887288
Capecitabine With Digoxin for Metastatic Breast Cancer treatment 2 terminated NCT01349088
Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer treatment 1 / 2 withdrawn NCT01516307
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects treatment 2 completed NCT01368107
Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients No drug interventions treatment 2 completed NCT01937507
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer No drug interventions treatment 2 terminated NCT00707707
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer treatment 1 completed NCT03062007
Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab No drug interventions treatment 1 terminated NCT01941407
First Line Metastatic Breast Cancer Treatment (ESMERALDA) treatment 2 completed NCT01973309
A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer treatment 1 completed NCT04495309
Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients With Oligometastatic Breast Cancer No drug interventions treatment Not Available recruiting NCT01506609
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer treatment 2 completed NCT01861509
BP-C1 in Metastatic Breast Cancer Patients No drug interventions basic_science 1 completed NCT00426556
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer treatment 1 completed NCT00434356
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) treatment 2 terminated NCT02506556
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer treatment 2 completed NCT04497285
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT04031885
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer treatment 4 terminated NCT04671615
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel. Not Available Not Available completed NCT00303615
Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer treatment 2 terminated NCT00735215
Faslodex Registry: Fulvestrant in Current Clinical Practice No drug interventions Not Available Not Available completed NCT03808337
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease No drug interventions treatment 2 recruiting NCT04571437
Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) treatment 2 unknown_status NCT06018337
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) treatment 3 recruiting NCT05283837
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) treatment 3 completed NCT05945732
DESTINY Breast Respond HER2-low Europe Not Available Not Available recruiting NCT02066532
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer treatment 1 / 2 completed NCT03562832
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP treatment 2 active_not_recruiting NCT01033032
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer treatment 1 / 2 completed NCT03127332
Metastatic Breast Cancer Treatment Planning No drug interventions supportive_care Not Available withdrawn NCT06533332
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors No drug interventions treatment 1 not_yet_recruiting NCT01957332
IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer No drug interventions diagnostic Not Available active_not_recruiting NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer treatment 1 recruiting NCT01956552
Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE) No drug interventions other Not Available terminated NCT02650752
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases treatment 1 completed NCT06377852
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study treatment 3 not_yet_recruiting NCT05142800
Screening For BCRL In Targeted Therapy For Breast Cancer No drug interventions Not Available Not Available recruiting NCT02624700
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer treatment 2 terminated NCT05021900
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer treatment 2 completed NCT04047459
Investigation of Cancer Cell Extravasation Through mRNA Analysis of Organ-specific Endothelial Cells and Microfluidics No drug interventions Not Available Not Available completed NCT05334459
Preoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer No drug interventions Not Available Not Available recruiting NCT06081959
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer treatment 3 recruiting NCT00601159
Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC treatment 2 completed NCT05744375
Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab treatment 2 recruiting NCT02000375
A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) treatment 2 terminated NCT00912275
Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer treatment 1 / 2 completed NCT03455270
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer treatment 1 completed NCT01113970
Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer treatment 1 / 2 unknown_status NCT00313170
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg treatment 2 completed NCT00876070
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT02094742
BIG Molecular Screening Feasibility Study No drug interventions screening Not Available completed NCT04296942
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) treatment 1 terminated NCT04538742
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer treatment 1 / 2 active_not_recruiting NCT01306942
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients treatment 1 / 2 completed NCT04197999
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer treatment 1 terminated NCT00316199
Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer treatment 2 completed NCT02299999
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer treatment 2 active_not_recruiting NCT01334099
Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients treatment 1 terminated NCT02642406
Therapy Management With Nab-Paclitaxel in Daily Routine No drug interventions Not Available Not Available unknown_status NCT04143906
Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer treatment 2 not_yet_recruiting NCT05759949
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors treatment 1 active_not_recruiting NCT00728949
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer treatment 2 completed NCT06151249
Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy No drug interventions treatment 2 not_yet_recruiting NCT00288249
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer treatment 2 completed NCT03591549
Fulvestrant in Metastatic Breast Cancer treatment 4 unknown_status NCT00524849
Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis treatment 2 / 3 completed NCT01025349
Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer treatment 2 completed NCT04024436
A Study of TAS-120 in Patients With Metastatic Breast Cancer treatment 2 active_not_recruiting NCT00764036
Study of Artesunate in Metastatic Breast Cancer treatment 1 completed NCT05977036
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer No drug interventions treatment Not Available not_yet_recruiting NCT00270413
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer treatment 2 completed NCT02109913
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane other Not Available unknown_status NCT05340413
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. diagnostic 2 recruiting NCT02626013
Real-world Evidence Prospective Study on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and HRQoL in Patients With MBC in Greece No drug interventions Not Available Not Available completed NCT02051218
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks supportive_care 3 active_not_recruiting NCT06048718
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases treatment 2 recruiting NCT01939418
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer treatment 1 / 2 terminated NCT04159818
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients treatment 2 recruiting NCT04262518
Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients No drug interventions health_services_research Not Available unknown_status NCT00319618
Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer treatment 2 completed NCT04012918
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study treatment 2 unknown_status NCT04740918
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) treatment 3 completed NCT04408118
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC treatment 2 completed NCT02470819
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer No drug interventions treatment Not Available withdrawn NCT03789019
BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment treatment 2 completed NCT04673019
Nurse AMIE for Echo Show: Randomized Control Trial No drug interventions supportive_care Not Available completed NCT06165419
Definitive Radiation for High-Risk Spine Metastases No drug interventions treatment 2 recruiting NCT04857619
Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients With HER2-positive Unresectable or Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT02422641
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis treatment 2 recruiting NCT05243641
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test treatment 1 / 2 recruiting NCT03755141
Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer treatment 2 unknown_status NCT03007641
Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient No drug interventions health_services_research Not Available completed NCT05131841
Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC treatment 4 unknown_status NCT03257917
Understanding Value in Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT04733417
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. treatment 2 unknown_status NCT02650817
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer treatment 1 completed NCT00634634
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer treatment 1 / 2 completed NCT00349934
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma treatment 1 completed NCT03323424
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers No drug interventions treatment 2 withdrawn NCT04796324
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. treatment 2 recruiting NCT01988324
AR and ER Imaging in Metastatic Breast Cancer No drug interventions diagnostic 2 completed NCT00983424
Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer treatment 1 completed NCT01108016
Expanding Rural Access: Distance Delivery of Support Groups (Main Study) No drug interventions Not Available 3 completed NCT02608216
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer diagnostic 1 active_not_recruiting NCT04092816
Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention No drug interventions supportive_care Not Available terminated NCT02409316
[18F]FES PET/CT in Endocrine Refractory Breast Cancer diagnostic 2 active_not_recruiting NCT02394496
Overcoming Endocrine Resistance in Metastatic Breast Cancer treatment 3 unknown_status NCT02555696
Abraxane in Treatment of Metastatic Breast Cancer Not Available Not Available completed NCT03530696
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer treatment 2 completed NCT05383196
Onvansertib + Paclitaxel In TNBC treatment 1 / 2 recruiting NCT05233696
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC treatment 2 withdrawn NCT02580396
Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine No drug interventions other Not Available completed NCT03892096
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer No drug interventions Not Available Not Available completed NCT04509596
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer treatment 1 active_not_recruiting NCT00525096
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer treatment 3 completed NCT02000596
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. treatment 2 terminated NCT01498458
Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer treatment 1 completed NCT05090358
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer treatment 2 active_not_recruiting NCT01658358
ErbB2 Positive Metastatic Breast Cancer treatment 1 / 2 terminated NCT02730858
Palliative And Oncology Care Model In Breast Cancer No drug interventions supportive_care Not Available completed NCT02642458
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients No drug interventions Not Available Not Available unknown_status NCT01416558
Nab-paclitaxel in Metastatic Breast Cancer Patients Failing Solvent Based Taxane (Tiffany) treatment 2 terminated NCT01616758
Phase II Study of GTx024 in Women With Metastatic Breast Cancer treatment 2 terminated NCT01942135
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) treatment 3 completed NCT03262935
SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer treatment 3 completed NCT02207335
Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer treatment 3 unknown_status NCT04247035
Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer No drug interventions Not Available Not Available unknown_status NCT05153135
Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors Not Available Not Available completed NCT04258735
Genetic Characteristics of Metastatic Breast Cancer Patients No drug interventions health_services_research Not Available unknown_status NCT04258163
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy Not Available Not Available completed NCT06386263
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada Not Available Not Available recruiting NCT04639986
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) treatment 3 active_not_recruiting NCT01392586
Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer No drug interventions treatment 3 terminated NCT04448886
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC treatment 2 active_not_recruiting NCT00508586
PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer treatment 1 completed NCT02605486
Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) treatment 1 / 2 active_not_recruiting NCT02474186
Phase II Study for Solid Metastatic Tumors treatment 2 completed NCT03148886
Advanced Breast Cancer and Lifestyle Exercise Study No drug interventions supportive_care Not Available completed NCT02384239
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer treatment 2 completed NCT05848739
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors treatment 1 recruiting NCT03901339
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer treatment 3 completed NCT02626039
Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients No drug interventions Not Available Not Available completed NCT05894239
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer treatment 3 recruiting NCT02581839
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate treatment 2 completed NCT06308939
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial treatment 2 not_yet_recruiting NCT03955939
A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body treatment 1 completed NCT06388122
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients No drug interventions Not Available Not Available recruiting NCT01626222
4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer treatment 3 completed NCT02000622
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. treatment 3 active_not_recruiting NCT04370522
Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT03143322
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases No drug interventions treatment Not Available recruiting NCT01029925
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL) treatment 2 terminated NCT01655225
A Study of LY3023414 in Participants With Advanced Cancer treatment 1 completed NCT00044525
Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients treatment 2 completed NCT01746225
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer treatment 2 completed NCT04374825
Optimizing Quality of Life in Women Living With Metastatic Breast Cancer No drug interventions supportive_care Not Available completed NCT02563925
Brain Irradiation and Tremelimumab in Metastatic Breast Cancer treatment Not Available completed NCT02864030
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment health_services_research 4 completed NCT00928330
Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy treatment 1 completed NCT05301530
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. treatment 1 completed NCT01323530
A Confirmation Study of Eribulin in Combination With Capecitabine treatment 1 / 2 completed NCT02913430
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib treatment 0 unknown_status NCT04699630
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer No drug interventions treatment 2 recruiting NCT05758948
Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer No drug interventions Not Available Not Available active_not_recruiting NCT00305448
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg treatment 2 completed NCT05721248
STOP-HER2: Stopping Trastuzumab in HER2+ MBC No drug interventions treatment 2 recruiting NCT02580448
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) treatment 1 / 2 completed NCT04608357
Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients No drug interventions Not Available Not Available unknown_status NCT05573126
Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer No drug interventions treatment 1 / 2 recruiting NCT05331326
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway No drug interventions treatment 2 unknown_status NCT05068726
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients Not Available Not Available terminated NCT04872166
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer No drug interventions treatment 1 recruiting NCT01653366
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway No drug interventions treatment Not Available terminated NCT00404066
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer treatment 2 completed NCT03703466
A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer treatment 2 completed NCT02668666
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer treatment 2 completed NCT00496366
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer treatment 2 terminated NCT00496665
ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer treatment 1 completed NCT02102165
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. No drug interventions screening Not Available recruiting NCT02315365
Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT00951665
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer treatment 1 / 2 completed NCT02001974
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) treatment 1 completed NCT03026374
Effect of a Mentor-based, Supportive-expressive Program on Survival in Metastatic Breast Cancer No drug interventions supportive_care Not Available unknown_status NCT06100874
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) treatment 2 recruiting NCT05079074
Clinical Application of Circulating Tumor DNA (ctDNA) in Patients With Late-stage Breast Cancer No drug interventions Not Available Not Available completed NCT04265274
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. treatment 2 withdrawn NCT00322374
Phase I Combination w/ Epirubicin treatment 1 completed NCT02966574
Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers No drug interventions diagnostic Not Available unknown_status NCT00773474
Lonafarnib in Metastatic Breast Cancer treatment 2 terminated NCT02939274
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer treatment 2 unknown_status NCT00428220
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. treatment Not Available completed NCT02448420
Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer treatment 2 completed NCT06551220
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns No drug interventions Not Available Not Available recruiting NCT05563220
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer treatment 1 / 2 recruiting NCT02790320
Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer No drug interventions Not Available Not Available completed NCT02445482
SOLTI Breast Cancer Molecular Screening Program (AGATA) No drug interventions Not Available Not Available completed NCT05486182
Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer diagnostic 4 recruiting NCT02424682
Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT04143282
Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment treatment 2 completed NCT06570031
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer treatment 1 active_not_recruiting NCT02111031
Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients No drug interventions Not Available Not Available withdrawn NCT06369831
HER2 Targeted Molecular Imaging in mBC Using 68Ga-ABS011 No drug interventions diagnostic 2 active_not_recruiting NCT01310231
A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer treatment 2 completed NCT02365831
Observation of Medical Treatments in MBC HER2-negative Patients No drug interventions Not Available Not Available unknown_status NCT01282931
Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT05086731
Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer No drug interventions health_services_research Not Available active_not_recruiting NCT04556773
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer treatment 1 active_not_recruiting NCT00156273
Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT00216073
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer treatment 2 terminated NCT05796973
Measuring Oncological Value of Exercise and Statin treatment 3 recruiting NCT01387373
Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer treatment 2 completed NCT00593827
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer treatment 2 completed NCT01609127
Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer treatment 2 unknown_status NCT00401427
HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer treatment 2 completed NCT02390427
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer treatment 1 active_not_recruiting NCT01663727
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer treatment 3 completed NCT05933876
The Impact of Radiotherapy on Oligometastatic Cancer No drug interventions Not Available Not Available recruiting NCT03636776
Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer No drug interventions supportive_care Not Available terminated NCT01084876
Demonstrate Efficacy and Safety of Metastatic Breast Cancer treatment 3 completed NCT05463276
The Characteristics and Risk Factors of Breast Cancer Patients Trend Distinctive Regional Differences: a Cross-sectional Study No drug interventions Not Available Not Available completed NCT01989676
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) treatment 3 completed NCT01660776
BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology No drug interventions Not Available Not Available completed NCT00442260
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer treatment 1 / 2 completed NCT04708860
Feasibility of Fasting & Exercise in Pts With HR+ MBC No drug interventions supportive_care Not Available completed NCT05079360
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer treatment 2 withdrawn NCT01633060
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi treatment 3 terminated NCT02163694
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer treatment 3 completed NCT01248494
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer treatment 1 completed NCT00790894
Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) treatment 2 terminated NCT01307891
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer treatment 2 completed NCT06459791
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid No drug interventions treatment Not Available not_yet_recruiting NCT00817362
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer treatment 2 terminated NCT04734262
A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) treatment 2 active_not_recruiting NCT01401062
Fresolimumab and Radiotherapy in Metastatic Breast Cancer treatment 2 completed NCT01300962
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer treatment 1 completed NCT02595762
A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer No drug interventions Not Available Not Available completed NCT01451580
Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer No drug interventions Not Available 2 unknown_status NCT01989780
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer treatment 2 completed NCT05176080
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer treatment 1 / 2 active_not_recruiting NCT00307229
Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1) No drug interventions treatment 1 completed NCT03368729
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer treatment 1 / 2 recruiting NCT00162929
Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe) No drug interventions treatment 1 completed NCT01238029
Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer treatment 1 terminated NCT00146029
Companion Pharmacogenetic Study to UMCC 9900/9901 No drug interventions Not Available Not Available terminated NCT03358589
Molecular Evaluation in Metastatic Breast Cancer No drug interventions diagnostic Not Available unknown_status NCT03045289
A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer No drug interventions treatment Not Available completed NCT01416389
A Study of LY2523355 in Participants With Breast Cancer treatment 2 completed NCT01067989
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer treatment 2 terminated NCT06517992
Collaborative cOMMUNIty Care for Metastatic breAsT cancEr Patients in inDonesia (Communicated) No drug interventions supportive_care Not Available not_yet_recruiting NCT01655992
A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC) treatment 3 terminated NCT06157892
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors treatment 1 / 2 recruiting NCT05735392
Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial) No drug interventions other Not Available completed NCT00952692
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer other 1 / 2 completed NCT03072992
"Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer treatment 2 completed NCT01935492
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer treatment 3 completed NCT03195192
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer No drug interventions other Not Available completed NCT03007992
Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer treatment 2 completed NCT01288092
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer treatment 2 withdrawn NCT01785992
A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer. treatment 2 completed NCT01910844
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes treatment 2 terminated NCT00600340
2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab treatment 3 completed NCT05141240
A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors Not Available Not Available completed NCT00452140
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment treatment 2 terminated NCT05544240
Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT06383767
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer treatment 3 recruiting NCT01256567
A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer treatment 1 completed NCT03970967
Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases No drug interventions treatment Not Available terminated NCT05463601
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer prevention 2 recruiting NCT06417801
Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer. No drug interventions Not Available Not Available recruiting NCT05567601
Doxil/Caelyx BE Study treatment 1 completed NCT01492101
The BEACON Study (Breast Cancer Outcomes With NKTR-102) treatment 3 completed NCT05552001
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer treatment 3 recruiting NCT05132101
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea Not Available Not Available active_not_recruiting NCT00169104
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function treatment 2 / 3 terminated NCT00431704
VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer treatment 2 active_not_recruiting NCT03763604
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer Not Available Not Available available NCT03982004
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer treatment 1 terminated NCT00894504
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer treatment 2 completed NCT05964504
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry) No drug interventions Not Available Not Available recruiting NCT01627704
Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer No drug interventions treatment Not Available completed NCT02747004
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer treatment 2 active_not_recruiting NCT05191004
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC treatment 1 / 2 withdrawn NCT05135104
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period Not Available Not Available recruiting NCT00532272
Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC treatment 2 completed NCT03051672
Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC treatment 2 terminated NCT02436772
Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC No drug interventions Not Available Not Available completed NCT05759572
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer treatment 2 recruiting NCT02344472
Detect V / CHEVENDO (Chemo vs. Endo) treatment 3 active_not_recruiting NCT04276272
D4 Choline Breast PET/CT No drug interventions Not Available Not Available completed NCT01161368
A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients treatment 2 terminated NCT05892068
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain treatment 2 recruiting NCT04252768
A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel treatment 1 withdrawn NCT03285568
Patterns of Prescribing and Monitoring of Palbociclib Not Available Not Available completed NCT00811369
Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer treatment 2 completed NCT04122469
The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease No drug interventions treatment Not Available recruiting NCT01526369
A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer treatment 3 completed NCT05652569
CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer No drug interventions Not Available Not Available recruiting NCT00241046
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment treatment 4 terminated NCT02863146
Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer No drug interventions Not Available Not Available terminated NCT06144346
Metastases Directed Therapy for Oligometastatic Breast Cancer No drug interventions treatment Not Available recruiting NCT00490646
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer treatment 2 completed NCT04215146
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study treatment 2 active_not_recruiting NCT00176046
Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study No drug interventions treatment 4 completed NCT06064812
A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. No drug interventions treatment 1 recruiting NCT02361112
Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer treatment 1 completed NCT00467012
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer treatment 2 completed NCT03245112
Halaven Patient Registry (Metastatic Breast Cancer, MBC) Not Available Not Available unknown_status NCT00691912
Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin treatment 2 terminated NCT05919212
Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy No drug interventions diagnostic Not Available recruiting NCT06072612
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. treatment 3 recruiting NCT01689610
Non-interventional Study With Nab-Paclitaxel (Abraxane®) No drug interventions Not Available Not Available completed NCT02051010
ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer? No drug interventions Not Available Not Available completed NCT01373710
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis treatment 1 / 2 completed NCT03241810
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer treatment 2 terminated NCT02651610
Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer treatment 2 / 3 withdrawn NCT02611310
A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC) No drug interventions Not Available Not Available terminated NCT00524810
Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer treatment 2 completed NCT06161181
Enhancing Therapy Adherence Among Metastatic Breast Cancer Patients No drug interventions other Not Available recruiting NCT01326481
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer treatment 1 / 2 completed NCT00807781
Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer No drug interventions treatment 1 completed NCT05900895
Estradiol Plus Olaparib for Breast Cancer (PHOEBE) treatment 1 not_yet_recruiting NCT06253195
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors treatment 1 recruiting NCT02753595
Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) treatment 1 / 2 terminated NCT00082095
To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older treatment 3 terminated NCT01387295
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease treatment 2 completed NCT06450314
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. No drug interventions treatment 2 not_yet_recruiting NCT00532714
Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC treatment 2 completed NCT01060514
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer treatment 1 terminated NCT00167414
Study for Using Radiosurgery on Limited Metastases of Breast Cancer No drug interventions treatment Not Available completed NCT05703555
INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701 treatment 2 withdrawn NCT01534455
Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) treatment 2 terminated NCT01715155
Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study No drug interventions Not Available Not Available completed NCT02965755
Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins No drug interventions treatment Not Available active_not_recruiting NCT05361655
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor Not Available Not Available completed NCT00265655
Satraplatin for Patients With Metastatic Breast Cancer (MBC) treatment 2 completed NCT05816655
Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer treatment 2 recruiting NCT02344550
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer treatment 2 completed NCT01814150
The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel No drug interventions Not Available Not Available unknown_status NCT03749850
Image-guided Targeted Doxorubicin Delivery With Hyperthermia to Optimize Loco-regional Control in Breast Cancer treatment 1 unknown_status NCT01792050
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer treatment 2 completed NCT04318223
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy treatment 2 unknown_status NCT06044623
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients No drug interventions treatment 3 recruiting NCT05577923
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) treatment 2 not_yet_recruiting NCT03863223
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer treatment 3 active_not_recruiting NCT00532623
Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer treatment 2 completed NCT05141708
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m Not Available Not Available completed NCT02829008
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients treatment 2 unknown_status NCT00303108
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer treatment 2 completed NCT04920708
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression treatment 2 recruiting NCT05534438
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer No drug interventions treatment 2 recruiting NCT02370238
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer treatment 2 completed NCT06408038
Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer No drug interventions other Not Available recruiting NCT06083038
Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib Not Available Not Available recruiting NCT03449238
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients treatment 1 / 2 recruiting NCT00890903
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC) No drug interventions Not Available Not Available completed NCT05609903
Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer Not Available Not Available completed NCT00915603
Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer treatment 2 completed NCT02102490
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread treatment 2 completed NCT03184090
Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC treatment 2 completed NCT06409390
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer treatment 0 recruiting NCT05865990
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease No drug interventions treatment 2 recruiting NCT06154590
Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor Not Available Not Available not_yet_recruiting NCT04095390
A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer treatment 2 unknown_status NCT02666690
Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast No drug interventions Not Available Not Available completed NCT04720664
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer No drug interventions treatment 2 terminated NCT04646564
Radiotherapy for Extracranial Oligometastatic Breast Cancer No drug interventions treatment 3 recruiting NCT00633464
Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer treatment 2 completed NCT03975621
Nurse AMIE: Addressing Metastatic Individuals Everyday No drug interventions supportive_care Not Available completed NCT01045421
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies treatment 1 / 2 completed NCT06489821
STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer No drug interventions treatment Not Available not_yet_recruiting NCT01240421
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory Not Available Not Available approved_for_marketing NCT01231802
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer treatment 2 unknown_status NCT01837602
cMet CAR RNA T Cells Targeting Breast Cancer No drug interventions treatment 1 completed NCT00334802
Combination Chemotherapy of Gemcitabine and Paclitaxel for Metastatic Breast Cancer treatment 2 completed NCT04579484
Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study No drug interventions Not Available Not Available unknown_status NCT05524584
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer treatment 2 recruiting NCT05963984
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants treatment 2 recruiting NCT04134884
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer treatment 1 completed NCT04683679
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer treatment 2 recruiting NCT05420779
A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations No drug interventions treatment 2 recruiting NCT03501979
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD treatment 2 active_not_recruiting NCT04478279
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT02101879
Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes No drug interventions Not Available Not Available unknown_status NCT04986579
Scalp Cooling in MBC supportive_care 2 recruiting NCT01843725
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers treatment 1 completed